Get the Stockscreener App
14.07
1.33%
-0.18
Oruka Therapeutics Inc stock is traded at $14.07, with a volume of 53,523.
It is down -1.33% in the last 24 hours and up +26.90% over the past month.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$14.25
Open:
$14.38
24h Volume:
53,523
Relative Volume:
0.25
Market Cap:
$527.54M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.11%
1M Performance:
+26.90%
6M Performance:
+19.66%
1Y Performance:
+0.00%
1-Day Range:
$13.86
$14.46
1-Week Range:
$13.51
$14.62
52-Week Range:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
14.09 | 533.53M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.53 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.25 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.58 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.95 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.07 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
What makes Oruka Therapeutics Inc. stock price move sharplyAchieve rapid returns with smart investment plans - jammulinksnews.com
Real time scanner hits for Oruka Therapeutics Inc. explainedPortfolio Positioning Strategy With Timing - Newser
Technical analysis overview for Oruka Therapeutics Inc. stockShort Term Opportunity Finder with Tools - Newser
What is Oruka Therapeutics Inc. company’s growth strategyGrow your wealth steadily and securely - jammulinksnews.com
What are the latest earnings results for Oruka Therapeutics Inc.High-octane financial growth - jammulinksnews.com
How does Oruka Therapeutics Inc. compare to its industry peersSky-high return potential - jammulinksnews.com
Is it the right time to buy Oruka Therapeutics Inc. stockDiscover undervalued stocks before they soar - jammulinksnews.com
Is Oruka Therapeutics Inc. a growth stock or a value stockInvest smarter with daily market updates - jammulinksnews.com
What catalysts could drive Oruka Therapeutics Inc. stock higher in 2025Maximize gains with timely market signals - jammulinksnews.com
What is the risk reward ratio of investing in Oruka Therapeutics Inc. stockStay ahead with advanced stock screening tools - jammulinksnews.com
What institutional investors are buying Oruka Therapeutics Inc. stockAchieve breakthrough performance in the market - jammulinksnews.com
How high can Oruka Therapeutics Inc. stock price go in 2025Free Stock Market Strategy Classes - Newser
How volatile is Oruka Therapeutics Inc. stock compared to the marketDouble-digit growth - jammulinksnews.com
Why Oruka Therapeutics Inc. stock attracts strong analyst attentionFree Investment Risk Control - Newser
What analysts say about Oruka Therapeutics Inc. stockBreakthrough financial growth - PrintWeekIndia
What drives Oruka Therapeutics Inc. stock priceLightning-fast capital gains - Autocar Professional
Is Oruka Therapeutics Inc. a good long term investmentTremendous financial leverage - PrintWeekIndia
printweek> 2025> Oruka Therapeutics Inc. Stock Analysis and ForecastBreakthrough profits - PrintWeekIndia
H.C. Wainwright reiterates Buy rating on Oruka Therapeutics stock as FDA clears IND - Investing.com Canada
Oruka Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Strong Buy Recommendation for Oruka Therapeutics: Promising Pipeline and Attractive Valuation - TipRanks
Oruka Therapeutics Shares Climb After FDA Greenlights Psoriasis Drug Trial - MSN
Oruka Therapeutics Inc. Stock Analysis and ForecastMassive profits - Autocar Professional
Wedbush Reiterates Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Announces IND Clearance for EVERLAST-A - GlobeNewswire
Oruka Therapeutics stock rises after FDA clears IND for psoriasis drug - Investing.com India
Stifel reiterates Buy rating on Oruka Therapeutics stock with $47 target - Investing.com Canada
Oruka Therapeutics: Revolutionizing Psoriasis Treatment with Extended-Dosing Biologics - AInvest
FDA clears Oruka’s IND for psoriasis drug ORKA-001 phase 2a trial - Investing.com
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September - Yahoo Finance
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Oruka Therapeutics Inc Stock (ORKA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
11.63 |
14,950 |
173,868 |
4,059,634 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
11.86 |
8,971 |
106,396 |
4,044,684 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
10.95 |
9,593 |
105,043 |
4,035,713 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
10.90 |
574 |
6,257 |
4,026,120 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Aug 16 '24 |
Buy |
2.93 |
5,818 |
17,067 |
2,117,213 |
1.05%
1.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):